Plant Summary

  Plant Information

TCMBank_ID:

TCMBANKHE006850

YEM_ID:

YEM-509

ID:

TCMBANKHE006850/YEM-509

植物拉丁名:

Papaver somniferum|Papaver somniferum L.
显示图片

功能与主治:

To fortify spleen and promote digestion, clear heat and disinhibit urine./Stomach reflux, abdominal pain, diarrhea, prolapse of rectum.

药用植物名:

罂粟

药名:

罂粟

来源:

云南民族药物志：第三卷

药用部位:

seed

使用民族:

傣族/基诺族/佤族/彝族

TCM_ID_id:

1389

   植物对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN005868 neopine CCG-39441; Neopin; C09594; KBio3_001981; EINECS 207-387-7; Spectrum2_001745; Spectrum4_001139; Spectrum5_001754; Neopine; DTXSID80196910; BSPBio_002761; SPBio_001850; SCHEMBL679477; UNII-TM43JB0IA8; 467-14-1; KBioGR_001657; (5alpha,6alpha)-8,14-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; 27115-17-9; CHEBI:7509; Spectrum3_001011; TM43JB0IA8; BRD-K34252131-001-02-0; beta-Codeine C18H21NO3 299.4 g/mol CN1CCC23C4C(CC=C2C1CC5=C3C(=C(C=C5)OC)O4)O
TCMBANKIN013157 thebaine C19H21NO3 311.4 g/mol CN1CCC23C4C(=CC=C2C1CC5=C3C(=C(C=C5)OC)O4)OC
TCMBANKIN014161 Protoporphyrin 553-12-8 (FREE ACID); NSC2632 (FREE ACID); protoporphyrin; Ferrocytochrome; PROTOPORPHYRIN (PP); Ferrocytochrome b-561 C34H34N4O4 562.66 CC1=C(C2=NC1=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=C2)[N-]5)C)CCC(=O)O)CCC(=O)O)C)C)C=C)C.[Fe+2]
TCMBANKIN014279 Papaverrubine B papaverrubine b C21H23NO6 385.4 g/mol COC1C2=C(C=CC3=C2OCO3)C4C(O1)C5=CC(=C(C=C5CCN4)OC)OC
TCMBANKIN018095 cycloartenone Cycloartenone; CYCLOARTENONE; CHEMBL226084; 511-63-7 C30H48O 424.7 CC(CCC=C(C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(=O)C5(C)C)C)C
TCMBANKIN018844 launobine C18H17NO4 311.3 g/mol COC1=C(C2=C(CC3C4=C2C5=C(C=C4CCN3)OCO5)C=C1)O
TCMBANKIN019205 Cryptogenin Cryptogenine; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione; cryptogenin; Cholest-5-ene-16,22-dione, 3beta,26-dihydroxy-, (20S,25R)- (8CI); Cryptogenine [French]; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione [French]; BXC9X8B37J; 3beta,26-Dihydroxycholest-5-ene-16,22-dione; UNII-BXC9X8B37J; NSC 93751; Cholest-5-ene-16,22-dione, 3-beta,26-dihydroxy-, (20S,25R)- (8CI); Cholest-5-ene-16,22-dione, 3,26-dihydroxy-, (3-beta,25R)-; (3-beta,25R)-3,26-Dihydroxycholest-5-ene-16,22-dione C27H42O4 430.62 [H+].CC(CCC(=O)C(C)C1C(=O)CC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)CO
TCMBANKIN020321 neoprotoveratrine C41H63NO15 809.9 g/mol CCC(C)C(=O)OC1C(C2C(CN3CC(CCC3C2(C)O)C)C4C1(C5C(C(C6C7(C5(C4)OC6(C(CC7)OC(=O)C(C)(C(C)O)O)O)C)OC(=O)C)OC(=O)C)O)O
TCMBANKIN020725 beta-narcotine AKOS003673314; IDI1_000323; CHEBI:95149; SCHEMBL14386820; β-narcotine; AC1L2EQH; MolPort-006-822-780; 6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; KBio1_000323; DivK1c_000323; CTK8G2016; NINDS_000323; LS-84359; 1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (R-(R*,R*))- C22H23NO7 413.4 g/mol CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3
TCMBANKIN020949 papaverine Cepaverin; AOB5339; 58-74-2; MFCD00012745; ZINC00056555; NCI60_003183; Drapavel; DSSTox_RID_77939; NCI-C56359; Myobid; BB_NC-0726; H754; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride; Papaverine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Dynovas; Artegodan; Papavarine chlorhydrate; DTXSID9025825; NCGC00094258-03; Isoquinoline,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride; 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; Alapav; Papacon; AIDS000185; NSC35443 (HCL); SMR000058283; KBioGR_000914; Spasmo-Nit; Papavarine hydrochloride; HMS1569F08; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-isoquinoline; DSSTox_CID_5825; Papaverine hydrochloride (JP17/USP); Pameion; NCGC00094258-06; BSPBio_002153; Chlorhydrate de papaverine [French]; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride (1:1); SBB080541; AIDS-000185; Oprea1_387689; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; I01-13837; Optenyl; CTK8G2272; Papaverine Hcl; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1; Dispamil; Lopac0_000957; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; Isoquinoline,7-dimethoxy-1-veratryl-, hydrochloride; MLS000028497; KBio2_005607; Lapav; Ro-Papav; Papanerin-HCl [German]; Cardiospan; Tox21_110226_1; TNP00305; Pavnell; HMS1920F06; LP00957; Pavagrant; SR-01000003098-2; SDCCGMLS-0003037.P003; AC1L1LRO; 6,7,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 6,7-Dimethoxy-1-veratrylisoquinoline; Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); TR-031684; Pavacot; Papaverine hydrochloride, United States Pharmacopeia (USP) Reference Standard; Paveron; Spectrum4_000467; Spectrum_000071; LS-267; SR-01000003098-11; Forpavin; Durapav; Cardoverina; Prestwick2_000583; Papaverine hydrochloride, powder; CCRIS 3804; 5-21-06-00182 (Beilstein Handbook Reference); Paverolan; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline; FT-0631269; ACon1_002094; NCGC00094258-04; EINECS 200-397-2; Papaverine; AC1Q3DLI; CHEMBL98123; Pavadel; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline hydrochloride; 58-74-2 (Parent); InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H; REGID_for_CID_6084; BBC/116; Dipav; NCGC00094258-01; P0016; SPBio_002645; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 6,7-Dimethoxy-1-veratrylisoquinoline hydrochloride; NCGC00261642-01; PubChem6305; Cerebid; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; Oprea1_810508; Vasal; Papanerin; P 3510; 23473EC6BQ; Pharmakon1600-01500459; C06533; Lopac-P-3510; Vaso-Pav; SCHEMBL121268; DivK1c_000321; Papaverina [Italian]; NSC136630; NSC 136630; KBio2_000471; Spectrum3_000537; MLS002222208; component of Copavin; 58-74-2 (FREE BASE ); Therapav; BG00717685; Prestwick1_000583; Pavacen; Copavin; AK-67336; Dilaves; PAP H; 4-[(6,7-dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene, chloride; UNII-23473EC6BQ; NCGC00015810-01; Papaversan; Tox21_500957; DSSTox_GSID_25825; Papaverine chlorohydrate; Papaverine hydrochloride [USAN:JAN]; EINECS 200-502-1; EU-0100957; Robaxapap; NCGC00094258-02; Papaverine hydrochloride [USP:JAN]; Papaverine, hydrochloride; Papaverine (hydrochloride); PAPAVERINE HYDROCHLORIDE; Prestwick0_000583; MEGxp0_001880; Delapav; D02218; Pavacap; BPBio1_000470; Ceraspan; AS-13262; NCGC00015810-03; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride; Papanerin-hcl; NCGC00015810-12; KB-146860; RS 47; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;hydrochloride; CAS-61-25-6; UOTMYNBWXDUBNX-UHFFFAOYSA-N; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride (1:1); Papaverin; ACon1_000238; KBio2_003039; Prestwick3_000583; Pavabid (TN); Papaverine monohydrochloride; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1 &GH; NSC757256; Pavatest; Papaverinium chloride; SR-01000003098; ST077145; ST023301; Pavakey; NSC-35443; BRN 0312930; Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI); SR-01000003098-9; 61-25-6 (HCL); SPBio_001015; NSC35443; MLS001148655; BSPBio_000426; IDI1_000321; Spectrum2_000978; Pavased; SPECTRUM1500459; Papanerine; NSC-757256; NCGC00094258-05; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)-isoquinoline hydrochloride; KBioSS_000471; HY-18077A; Papaverine hydrochloride, European Pharmacopoeia (EP) Reference Standard; BG01663857; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinolinehydrochloride; S-M-R; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; NINDS_000321; Papalease; Papaverine hydrochlorid; KBio3_001653; Pap-Kaps-150; MolPort-000-847-203; NCGC00015810-02; Isoquinoline, 6,7-dimethoxy-1-veratryl-; API0003748; CCG-40065; CS-5015; BAS 00674058; ARONIS23834; AKOS005111070; 61-25-6; NSC 35443; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; C20H22ClNO4; 1-(3,7-dimethoxyisoquinoline hydrochloride; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride (8CI); Tox21_110226; 6,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; Spectrum5_001188; Opera_ID_1617; Prestwick_376; SR-01000003098-4; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-; KBio1_000321 C20H21NO4 339.39 COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
TCMBANKIN021575 glaudine C22H25NO6 399.4 g/mol CN1CCC2=CC(=C(C=C2C3C1C4=C(C(O3)OC)C5=C(C=C4)OCO5)OC)OC
TCMBANKIN021670 Thellungianin F [4-[(Z)-prop-1-enyl]phenyl] 2-methylbutanoate; AC1NT0ZM; thellungianin f 218.32 CCC(C)C(=O)OC1=CC=C(C=C1)C=CC
TCMBANKIN021931 laudanosine C21H27NO4 357.44 CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC
TCMBANKIN025334 parasorbic acid Parascorbic acid; Kyselina paraskorbova; CHEBI:7926; AC1L9BCD; (+)-(6S)-PARASORBIC ACID; (2S)-2-methyl-2,3-dihydropyran-6-one; gamma-Hexenolactone; parasorbicacid; DCN48OUK3T; AKOS006278774; (S)-(+)-5,6-Dihydro-6-methyl-2H-pyran-2-one; Sorbic oil; C08502; Kyselina paraskorbova [Czech]; CHEMBL2252704; 2-Hexenoic acid, 5-hydroxy-, delta-lactone; Parasorbic acid; UNII-DCN48OUK3T; 2-Hexen-5,1-olide; 10048-32-5; (+)-Parasorbinsaeure [German]; (s)-2-hexen-5-olide; 2H-Pyran-2-one, 5,6-dihydro-6-methyl-, (6S)-; 5-17-09-00130 (Beilstein Handbook Reference); (+)-Parasorbinsaeure; BRN 0080685; SCHEMBL2686203; Hexenollactone C6H8O2 112.13 g/mol CC1CC=CC(=O)O1
TCMBANKIN025420 codeine Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; HSDB 3043; O(3)-methylmorphine; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol; C06174; l-Codeine; CCRIS 7555; Morphine monomethyl ether; C1653_SIGMA; Methylmorphine; Codeine; CHEBI:16714; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol; (5alpha,6alpha)-17-methyl-3-(methyloxy)-7,8-didehydro-4,5-epoxymorphinan-6-ol; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8CI); Coducept; Norcodeine, N-methyl; 76-57-3; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5-alpha,6-alpha)- (9CI); Codicept; Morphine-3-methyl ester; Codeine anhydrous; O3-Methylmorphine; EINECS 200-969-1; Morphine 3-methyl ether; Norcodine, N-methyl; Codein; Morphine-3-methyl ether; STOCK1N-42851; (-)-Codeine; Codeine solution; BB_NC-0138; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9CI); 7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; C5901_SIGMA; Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- C18H21NO3 299.36 CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O
TCMBANKIN028288 morphine (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; RMS; Hard stuff; Morpho; Cube juice; 47106-99-0; EINECS 200-320-2; 64-31-3 (SULFATE); (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphin; Nepenthe; Roxanol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; CCRIS 5762; AIDS-001987; Moscontin; Statex SR; Unkie; Morphia; Morphina [Italian]; M-Eslon; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; Morphinum; Ms Emma; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Dolcontin; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; Morphinism; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE; 57-27-2 (FREE BASE ); (-)-Morphine; Dulcontin; 8053-16-5; Meconium; (-)Morphine sulfate; Ospalivina; NSC11441(SULFATE); Morphium; Morphin [German]; l-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; Dreamer; HSDB 2134; Hocus; 85201-37-2; AIDS001987; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; DEA No. 9300; Duromorph; Morfina [Italian]; Morphina; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; MOI; CHEBI:17303 C17H19NO3 285.34 CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
TCMBANKIN028295 retrorsine .beta.-Longilobine; BCJMNZRQJAVDLD-XRVQXMHSSA-N; RETRORSINE C18H25NO6 351.4 g/mol CC=C1CC(C(C(=O)OCC2=CCN3C2C(CC3)OC1=O)(CO)O)C
TCMBANKIN034931 Narcotoline 3-(4-hydroxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxy-3H-2-benzofuran-1-one; 6-Methyl-4-hydroxy-5,6,7,8-tetrahydro-5-(3-oxo-4,5-dimethoxy-1,3-dihydroisobenzofuran-1-yl)-1,3-dioxolo[4,5-g]isoquinoline; AC1MRPAC; narcotoline C21H21NO7 399.39 CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)O)OCO3
TCMBANKIN036915 morroniside Morroniside; HMS2205G07; SMR001397097; MLS002472991; CHEMBL2136065 C17H26O11 406 [C@@]1([H])(O[H])C([H])([H])[C@@]([H])(C(C(OC([H])([H])[H])=O)=C([H])O[C@@]2([H])O[C@@]3([H])O[C@]([H])(C([H])([H])O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]3([H])O[H])[C@@]2([H])[C@]([H])(C([H])([H])[ H])O1
TCMBANKIN044898 fluorocarpamine C20H23N2O3+ 339.4 g/mol CC=C1C[NH+]2CCC34C2CC1C(N3C5=CC=CC=C5C4=O)C(=O)OC
TCMBANKIN049686 cycloartenol CF58DF82-6B90-40E1-B241-3FA99C98DA64; Cycloartenol; 9,19-Cyclolanost-24-en-3-ol, (3beta)-; C01902; 9beta,19-Cyclo-24-lanosten-3beta-ol; SCHEMBL561141; Cycloarterenol; 469-38-5; NSC 670193 C30H50O 426.7 g/mol CC(CCC=C(C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(C5(C)C)O)C)C
TCMBANKIN058003 sanguinarine Sanguinarine, 8CI); NSC-59270; sanguinarine ; NSC-35607; [1,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-, nitrate,sanguiritrin C20H14NO4+ 332.3 g/mol C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6
TCMBANKIN058114 trans-caffeic acid 3-(3,4-dihydroxy-phenyl)-acrylic acid; caffeic acid; Caffeate; Lopac-C-0625; 71693-97-5; DivK1c_006624; KBio2_007302; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NCGC00015206-02; CAS-3331-39-5; 60020_FLUKA; AI3-63211; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid polymer; (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NSC623438; 4-(2'-Carboxyvinyl)-1,2-dihydroxybenzene; KBio2_004734; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; CHEMBL1320034; AIDS-002287; AIDS002287; 501-16-6; CHEBI:36281; Prestwick1_000902; KBio1_001568; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; AKOS000273846; OR1165; SMR000058214; Spectrum2_001612; 3,4-dihydroxycinnamate; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeicacid; KOP; AC1NO658; CCRIS 847; Caffeic acid dehydrogenation homopolymer; SPECTRUM1503987; Spectrum4_001694; SCHEMBL3682144; NCGC00017364-01; NCGC00022654-08; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene; 78734C5A-1281-44D4-B8A0-A3188AD437E3; cis-Caffeic acid; 3-(3,4-dihydroxyphenyl)acrylic acid; Cinnamic acid, 3,4-dihydroxy-; KBioGR_001988; 3,4-Dihydroxybenzeneacrylic acid; 3,4-dihydroxycinnamic acid; trans-caffeic acid; AIDS-026339; NCGC00015206-01; HSDB 7088; ZINC4482687; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; 3-(3,4-dihydroxyphenyl)prop-2-enoate; Isocaffeic acid; SBB006475; InChI=1/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2; NCGC00017364-02; EU-0100208; C01197; MolPort-001-759-162; KBioSS_002166; Caffeic acid pure; caffeic acid ; trans-Caffeate; (2E)-3-(3,4-dihydroxyphenyl)acrylic acid; NSC 57197; (2E)-3-(3,4-Dihydroxyphenyl)-2-propenoic acid; Spectrum_001686; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, (E)-; KBio2_002166; Caffeic acid, cis-; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; 3,4-Dihydroxybenzeneacrylate; 3-(3,4-Dihydroxy phenyl)-2-propenoic acid; 4361-87-9; 3,4-Dihydroxy-trans-cinnamate; caffeicacid; AR-360/40806927; EINECS 206-361-2; 60018_FLUKA; Caffeic acid polymer; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; NCGC00022654-04; ZX-AL002121; C0625_SIGMA; SDCCGMLS-0002982.P003; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid, homopolymer; SPBio_001643; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)- (9CI); NCGC00017364-03; 3-(3,4-dihydroxyphenyl)prop-2-enoic acid; AC1LU7RL; SPBio_002943; CHEBI:16433; AIDS026339; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, homopolymer; CHEBI:17395; TNP00311; SpecPlus_000528; Prestwick0_000902; MLS000069738; 3,4-dihydroxy-cinnamic acid; 3-(3,4-Dihydroxyphenyl)propenoic acid; NCI60_004400; NSC57197; Caffeic; Lopac-C-0625; NCGC00015206-01; Caffeic acid; cis-Caffeic acid; NCGC00017364-01; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; C01481; 331-39-5; NCGC00015206-02; CAS-3331-39-5; 3,4-Dihydroxycinnamic acid; CHEBI:17395; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; TNP00311; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeate; 1- coffee acid C9H8O4 180.16 g/mol C1=CC(=C(C=C1C=CC(=O)O)O)O
TCMBANKIN059820 atractylenolide iii; codonolactone C15H20O3 248.32 CC1=C2CC3C(=C)CCCC3(CC2(OC1=O)O)C
TCMBANKIN060679 stigmasterol C29H48O 412.7 g/mol CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C
TCMBANKIN060680 stigmasterol-3-glucoside C35H58O6 574.83 g/mol CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC5C(C(C(C(O5)CO)O)O)O)C)C)C(C)C
TCMBANKIN060947 Sanleng acid C18H34O5 330.46 CCCCCCCCC(C(C=CC(CCCCC(=O)O)O)O)O
TCMBANKIN061104 11-oxotriacontanoic acid C30H58O3 466.8 g/mol CCCCCCCCCCCCCCCCCCCC(=O)CCCCCCCCCC(=O)O
TCMBANKIN061320 cryptopine C21H23NO5 369.41 CN1CCC2=CC(=C(C=C2C(=O)CC3=C(C1)C4=C(C=C3)OCO4)OC)OC
TCMBANKIN061324 d-reticuline (S)-(+)-reticuline; (1S)-1-[(3-hydroxy-4-methoxy-phenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; CHEBI:16718; 485-19-8; (1S)-1-(3-hydroxy-4-methoxy-benzyl)-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; (+)-Reticuline; (1S)-1-(3-hydroxy-4-methoxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; (1S)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; C02105;CHEBI:17428; AC1L99KR; (R)-(-)-reticuline; (1R)-1,2,3,4-Tetrahydro-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-7-isoquinolinol; AK552295; (1R)-1-(3-hydroxy-4-methoxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; C05178; FT-0699770; MFCD28556897; ZINC901258; DTXSID80331501; L-Reticuline; CHEMBL401501; AKOS030242061; (1R)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; (R)-Reticuline; (-)-reticuline; SCHEMBL9587509; NCGC00247617-01; 3968-19-2; (R)-Reticuline (>80% ee); CTK1C2641; (S)-Reticuline;reticuline;reticulin C19H23NO4 329.4 g/mol CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)O)O)OC
TCMBANKIN061334 glaucine AC1LL50T; (R)-5,6,6a,7-Tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo(de,g)quinoline; 38325-02-9; ZINC792622; EINECS 253-881-0; 4H-Dibenzo(de,g)quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, (R)-; FT-0698454; (?)-Glaucine; RUZIUYOSRDWYQF-OAHLLOKOSA-N; l-Glaucine; DTXSID70191691; (R)-5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo[de,g]quinoline; Glauvent ;(-)-glaucine; Bromcholitin; (+)-Glaucine; AIDS011385; GLAUCINE,(D); Glaucine; 6a.alpha.-Aporphine, 1,2,9,10-tetramethoxy-; NSC34396; S-(+)-Glaucine; C09446; Glaucine fumarate; BB_NC-0833; d-Glaucine; 4H-Dibenzo[de,g]quinoline, 5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-, (S)-; Boldine dimethyl ether; 475-81-0; AIDS-011385 C21H25NO4 355.43 CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)OC)OC)OC
TCMBANKIN061352 longatin (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; NSC121869; SMR000059119; (S,R)-Noscapine; C09592; STK054401; BSPBio_000346; 128-62-1; AIDS011873; (3S)-3-[(5R)-6-methyl-4-(methyloxy)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-bis(methyloxy)-2-benzofuran-1(3H)-one; Lopac0_000840; Tocris-1697; Noscapine (TN); alpha-Narcotine; .beta.-Narcotine; alpha-narcotine; EINECS 204-899-2; Noscapine [BAN:INN:JAN]; Coscopin (VAN); L-alpha-Narcotine; 4-27-00-06838 (Beilstein Handbook Reference); 1368-39-4; Lopac-N-9007; 1(3H)-Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)-isoquinolin-5-yl),(S-(R*,S*))-; L-alpha-Noscapine; CAS-128-62-1; BRN 0099933; BSPBio_002113; SDCCGMLS-0066644.P001; 1(3H)-Isobenzofuranone,6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-,(S-(R*,S*))-; HSDB 3372; KBio2_004117; TNP00110; SPBio_001053; (3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one; NCGC00017174-02; 567-86-2; KBio2_006685; Spectrum5_001276; (-)-alpha-Norcotine; NCGC00017174-01; KBioGR_000872; Spectrum2_000987; (3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one; Noscapinum [INN-Latin]; NCGC00015757-01; Spectrum_001069; KBio3_001613; ST055757; (-)-Narcotine; Spectrum3_000527; 8-Methoxyhydrastin; 5-(6,7-Dimethoxyphthalidyl)-5,6,7,8-tetrahydro-4-methoxy-8-methyl-1,3-dioxolo(4,5-g)isoquinoline; L-alpha-2-Methyl-8-methoxy-6,7-methylenedioxy-1-(6,7-dimethoxy-3-phthalidyl)-1,2,3,4-tetrahydroisoquinaline; TNP00034; KBio2_001549; Spectrum4_000456; Longactin; 8057-19-0; Noscapina [INN-Spanish]; KBioSS_001549; (-)-3-(2-Methyl-6,7-methylendioxy-8-methoxy-1-isochinolyl)-6,7-dimethoxyphthalid; NCGC00016388-01; Narcotine (8CI); 8055-18-3; NCGC00023230-02; AIDS-011873; D01036; CBMicro_048259; SPBio_002565; BIM-0048054.P001; NCI60_004322; Prestwick1_000563; Prestwick3_000563; (-)-.alpha.-Narcotine; Prestwick_959; (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one; MLS000069475; 363960_ALDRICH; BPBio1_000382; Coscopin; Methoxyhydrastine; Prestwick0_000563; Prestwick2_000563; Noscapine (JP15/USP/INN); AC1NSW29; 5-[(1S)-4,5-dimethoxy-3-methylidene-1H-2-benzofuran-1-yl]-4-methoxy-6,9-dimethyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinoline; narcotine; Noscapine; gnoscopine; Noskapin; α-narcotine C22H23NO7 413.42 g/mol CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3
TCMBANKIN061354 Fumarine C05189; TNP00339; 7-methyl-2,3:9,10-bis[methylenebis(oxy)]-7,13a-secoberbin-13a-one; ST036759; Bis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-13(5H)-one, 4,6,7,14-tetrahydro-5-methyl-; Bis(1,3)benzodioxolo(4,5-c:5',6'-g)azecin-13(5H)-one, 4,6,7,14-tetrahydro-5-methyl-; HSCI1_000268; EINECS 204-999-6; AIDS-040935; Corydinine; 4,6,7,14-Tetrahydro-5-methyl-bis(1,3)benzodioxolo(4,5-c-5',6'-g)azecin-13(5H)-one; Oprea1_722246; NCGC00142402-01; Biflorine; Macleyine; 130-86-9; NCGC00017389-01; 7-methyl-6,8,9,16-tetrahydrobis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-15(7H)-one; 7,13a-Secoberbin-13a-one, 7-methyl-2,3:9,10-bis(methylenedioxy)-; Alk-3; 6164-47-2 (HCL); Oprea1_718853; AIDS040935; 7-Methyl-2,3:9,10-bis(methylenedioxy)-7,13a-secoberbin-13a-one; HSDB 3527; CHEBI:16415; AI3-62909; ACon1_001550; DTXSID00178935; Bis(1,3)benzodioxolo(5,6-c:5',6'-g)azecin-14(6H)-one, 5,7,8,15-tetrahydro-6-methyl-; Bis[1,3]benzodioxolo[5,6-c:5',6'-g]azecin-14(6H)-one,5,7,8,15-tetrahydro-6-methyl-; AC1L4H3I; CHEMBL486179; 14-METHYL-7,9,20,22-TETRAOXA-14-AZAPENTACYCLO[15.7.0.0?,(1)(2).0?,(1)?.0(1)?,(2)(3)]TETRACOSA-1(24),4,6(10),11,17,19(23)-HEXAEN-2-ONE; CTK4F3162; MCULE-2865552640; BDBM50377937; 24240-05-9; AC1Q6P91; NCGC00385257-01_C20H19NO5_1,3-Benzodioxolo[5,6-c][1,3]benzodioxolo[5,6-g]azecin-14(6H)-one, 5,7,8,15-tetrahydro-6-methyl-; C20H19NO5; protopine ; Pseudoprotopine; MolPort-028-610-216; 6-methyl-5,7,8,15-tetrahydrobis[1,3]benzodioxolo[5,6-c:5',6'-g]azecin-14(6h)-one; 7,13a-Secoberbin-13a-one, 7-methyl-2,3:10,11-bis(methylenedioxy)-; ZINC31502517; protopine C20H19NO5 353.37 CN1CCC2=CC3=C(C=C2C(=O)CC4=C(C1)C5=C(C=C4)OCO5)OCO3
TCMBANKIN061462 m-hemipicacid metahemipic acid C10H10O6 226.18 g/mol COC1=C(C=C(C(=C1)C(=O)O)C(=O)O)OC
   植物对应的疾病
疾病ID 病名 疾病类型 MeSH 参考文献
   植物对应的靶点
靶点ID 基因名 基因别名 描述 染色体位置 Map_Location 基因类型

Home | Browse | Search | Predict | Data | Contact | Help

Copyright © KUST | 滇ICP备16009434号-1 | Dai SX Lab